<p>Pacer Advisors Inc. 在最近向美国证券交易委员会提交的 13F 表格中表示，在第三季度将其在安进公司（NASDAQ:AMGN - 免费报告）的股份减少了 8.8%。该公司在季度内出售了 155,180 股后，持有 1,613,121 股该医疗研究公司的股票。安进大约占 Pacer Advisors Inc. 投资组合的 1.1%，是其第九大持仓。截止最近报告期末，Pacer Advisors Inc. 持有的安进股份价值 4.55223 亿美元，占比 0.30%。</p>
<ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
<p>其他对冲基金最近也对该公司的持仓进行了调整。Fairvoy Private Wealth LLC 在第二季度将其在安进的持仓增加了 1.1%。Fairvoy Private Wealth LLC 目前持有 3,171 股该医疗研究公司的股票，价值 885,000 美元，在此期间又购买了 35 股。Nicholson Wealth Management Group LLC 在第二季度将其在安进的股份增加了 0.6%。Nicholson Wealth Management Group LLC 目前持有 5,918 股该医疗研究公司的股票，价值 1,652,000 美元，在上个季度又收购了 35 股。Crumly &amp; Associates Inc. 在第二季度将其在安进的持仓增加了 3.2%。Crumly &amp; Associates Inc. 目前持有 1,146 股该医疗研究公司的股票，价值 320,000 美元，在此期间又购买了 36 股。Maryland Capital Advisors Inc. 在第二季度将其在安进的股份增加了 5.2%。Maryland Capital Advisors Inc. 目前持有 732 股该医疗研究公司的股票，价值 204,000 美元，在上个季度又购买了 36 股。最后，Lion Street Advisors LLC 在第二季度将其在安进的持仓增加了 1.3%。Lion Street Advisors LLC 目前持有 2,773 股该医疗研究公司的股票，价值 774,000 美元，在此期间又购买了 36 股。76.50% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>内部交易活动</h2>
<p>在其他消息中，SVP Rachna Khosla 于 11 月 12 日星期三出售了 890 股该公司的股票。股票以平均价格 336.24 美元出售，总价值为 299,253.60 美元。出售后，该高级副总裁直接持有 7,082 股公司的股票，价值 2,381,251.68 美元。此次交易使其持仓减少了 11.16%。该出售在向美国证券交易委员会提交的文件中披露，文件可通过美国证券交易委员会网站获取。此外，EVP Murdo Gordon 于 11 月 12 日星期三出售了 6,879 股公司的股票。股票以平均价格 336.83 美元出售，总价值为 2,317,053.57 美元。出售完成后，该执行副总裁持有 41,923 股公司股票，价值 14,120,924.09 美元。此次交易使其持仓减少了 14.10%。有关此次出售的更多细节可在官方的美国证券交易委员会披露中找到。在过去的九十天里，内部人士出售了价值 3,674,966 美元的 10,908 股公司股票。内部人士持有公司股票的 0.76%。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>5 家医疗公司值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>几家研究公司对安进发表了看法。Truist Financial 于 11 月 24 日星期一开始对安进进行覆盖。他们对该公司给予了 “持有” 评级，并设定了 318.00 美元的目标价。美国银行在 9 月 26 日星期五的研究报告中将安进的目标价从 261.00 美元上调至 272.00 美元，并给予该股票 “表现不佳” 的评级。高盛集团在 11 月 25 日星期二的研究报告中重申了对安进股票的 “买入” 评级。富国银行在 12 月 10 日星期三的研究报告中将安进股票的目标价从 300.00 美元上调至 325.00 美元，并给予该股票 “等权重” 的评级。最后，Piper Sandler 在 11 月 14 日星期五的研究报告中将安进股票的目标价从 342.00 美元上调至 381.00 美元，并给予该公司 “超配” 的评级。一位分析师对该股票给予了强烈买入评级，十位分析师给予了买入评级，十位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat，安进目前的平均评级为 “适度买入”，共识目标价为 332.85 美元。</p>
<p><strong>查看我们关于安进的最新报告</strong></p>
<h2>安进股票表现</h2>
<ul>
<li>安进股票：在盈利超预期后，新的历史高点即将到来</li>
</ul>
<p>安进股票在星期五开盘价为 332.50 美元。该公司的流动比率为 1.28，速动比率为 0.99，债务与股本比率为 5.45。该公司的市值为 1,790.4 亿美元，市盈率为 25.70，市盈增长比率为 3.10，贝塔系数为 0.45。该公司的 50 日简单移动平均为 322.29 美元，200 日简单移动平均为 301.33 美元。安进的 12 个月低点为 257.05 美元，12 个月高点为 346.38 美元。</p>
<p>安进（NASDAQ:AMGN - 获取免费报告）最近于 11 月 4 日星期二发布了其财报。这家医疗研究公司报告了每股收益 5.64 美元，超出分析师一致预期的 5.01 美元，超出幅度为 0.63 美元。该公司在本季度的收入为 95.6 亿美元，而一致预期为 89.8 亿美元。安进的净利润率为 19.47%，股本回报率为 162.59%。与去年同期相比，该公司的收入增长了 12.4%。在去年同期，该公司每股收益为 5.58 美元。安进已将其 2025 财年指引设定为每股收益 20.600-21.400 美元。分析师平均预测安进在当前财年将发布每股收益 20.62 美元。</p>
<h2>安进增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 3 月 6 日（星期五）支付。2 月 13 日（星期五）登记在册的股东将获得每股 2.52 美元的股息。这是对安进之前每股 2.38 美元季度股息的积极调整。这相当于年化 10.08 美元的股息，股息收益率为 3.0%。该股息的除息日期为 2 月 13 日（星期五）。安进的派息比率为 73.57%。</p>
<h2>安进简介</h2>
<p>(免费报告)</p>
<p>安进公司（NASDAQ: AMGN）是一家成立于 1980 年，总部位于加利福尼亚州千橡市的全球生物技术公司。该公司专注于发现、开发、生产和提供针对严重疾病的人类治疗药物。安进的工作重点是基于细胞和分子生物学的生物药物，强调将人类遗传学和蛋白质科学的进展转化为患者的治疗方案。</p>
<p>安进的商业产品组合历来包括用于肿瘤学、支持性护理、肾脏病、骨骼健康和心血管疾病的生物制剂。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过安进</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>华盛顿为战争做准备</li>
<li>在 1 月 1 日之前投资 1000 美元于这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
</ul>
<p><strong>想知道其他对 AMGN 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取安进公司（NASDAQ:AMGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元于安进吗？</h2>
<p>在考虑安进之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而安进并不在其中。</p>
<p>虽然安进目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

安进

<p>Pacer Advisors Inc. 在第三季度减少了对安进（Amgen Inc.）的持股比例，下降了 8.8%，目前持有 1,613,121 股。安进占 Pacer 投资组合的 1.1%。其他公司在第二季度调整了对安进的持股。内部人士出售了 10,908 股，价值 367 万美元。分析师对安进的评级不一，普遍认为为 “适度买入”，目标价为 332.85 美元。安进的股票开盘价为 332.50 美元</p>

<p>Pacer Advisors Inc. lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 8.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,613,121 shares of the medical research company's stock after selling 155,180 shares during the quarter. Amgen makes up approximately 1.1% of Pacer Advisors Inc.'s portfolio, making the stock its 9th biggest position. Pacer Advisors Inc. owned 0.30% of Amgen worth $455,223,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Pacer Advisors Inc. 在最近向美国证券交易委员会提交的 13F 表格中表示，在第三季度将其在安进公司（NASDAQ:AMGN - 免费报告）的股份减少了 8.8%。该公司在季度内出售了 155,180 股后，持有 1,613,121 股该医疗研究公司的股票。安进大约占 Pacer Advisors Inc. 投资组合的 1.1%，是其第九大持仓。截止最近报告期末，Pacer Advisors Inc. 持有的安进股份价值 4.55223 亿美元，占比 0.30%。</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
</div><p>Other hedge funds also recently made changes to their positions in the company. Fairvoy Private Wealth LLC boosted its position in Amgen by 1.1% during the 2nd quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company's stock valued at $885,000 after buying an additional 35 shares during the period. Nicholson Wealth Management Group LLC raised its stake in shares of Amgen by 0.6% during the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company's stock valued at $1,652,000 after acquiring an additional 35 shares during the last quarter. Crumly &amp; Associates Inc. boosted its holdings in shares of Amgen by 3.2% during the second quarter. Crumly &amp; Associates Inc. now owns 1,146 shares of the medical research company's stock worth $320,000 after purchasing an additional 36 shares during the period. Maryland Capital Advisors Inc. grew its stake in shares of Amgen by 5.2% in the second quarter. Maryland Capital Advisors Inc. now owns 732 shares of the medical research company's stock worth $204,000 after purchasing an additional 36 shares during the last quarter. Finally, Lion Street Advisors LLC increased its holdings in Amgen by 1.3% during the 2nd quarter. Lion Street Advisors LLC now owns 2,773 shares of the medical research company's stock valued at $774,000 after purchasing an additional 36 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他对冲基金最近也对该公司的持仓进行了调整。Fairvoy Private Wealth LLC 在第二季度将其在安进的持仓增加了 1.1%。Fairvoy Private Wealth LLC 目前持有 3,171 股该医疗研究公司的股票，价值 885,000 美元，在此期间又购买了 35 股。Nicholson Wealth Management Group LLC 在第二季度将其在安进的股份增加了 0.6%。Nicholson Wealth Management Group LLC 目前持有 5,918 股该医疗研究公司的股票，价值 1,652,000 美元，在上个季度又收购了 35 股。Crumly &amp; Associates Inc. 在第二季度将其在安进的持仓增加了 3.2%。Crumly &amp; Associates Inc. 目前持有 1,146 股该医疗研究公司的股票，价值 320,000 美元，在此期间又购买了 36 股。Maryland Capital Advisors Inc. 在第二季度将其在安进的股份增加了 5.2%。Maryland Capital Advisors Inc. 目前持有 732 股该医疗研究公司的股票，价值 204,000 美元，在上个季度又购买了 36 股。最后，Lion Street Advisors LLC 在第二季度将其在安进的持仓增加了 1.3%。Lion Street Advisors LLC 目前持有 2,773 股该医疗研究公司的股票，价值 774,000 美元，在此期间又购买了 36 股。76.50% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, SVP Rachna Khosla sold 890 shares of the business's stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president directly owned 7,082 shares of the company's stock, valued at $2,381,251.68. The trade was a 11.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the company's stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 10,908 shares of company stock worth $3,674,966. Insiders own 0.76% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，SVP Rachna Khosla 于 11 月 12 日星期三出售了 890 股该公司的股票。股票以平均价格 336.24 美元出售，总价值为 299,253.60 美元。出售后，该高级副总裁直接持有 7,082 股公司的股票，价值 2,381,251.68 美元。此次交易使其持仓减少了 11.16%。该出售在向美国证券交易委员会提交的文件中披露，文件可通过美国证券交易委员会网站获取。此外，EVP Murdo Gordon 于 11 月 12 日星期三出售了 6,879 股公司的股票。股票以平均价格 336.83 美元出售，总价值为 2,317,053.57 美元。出售完成后，该执行副总裁持有 41,923 股公司股票，价值 14,120,924.09 美元。此次交易使其持仓减少了 14.10%。有关此次出售的更多细节可在官方的美国证券交易委员会披露中找到。在过去的九十天里，内部人士出售了价值 3,674,966 美元的 10,908 股公司股票。内部人士持有公司股票的 0.76%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家医疗公司值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>Several research firms have weighed in on AMGN. Truist Financial began coverage on Amgen in a report on Monday, November 24th. They issued a &#34;hold&#34; rating and a $318.00 price objective for the company. Bank of America raised their price target on Amgen from $261.00 to $272.00 and gave the stock an &#34;underperform&#34; rating in a research note on Friday, September 26th. The Goldman Sachs Group reissued a &#34;buy&#34; rating on shares of Amgen in a research report on Tuesday, November 25th. Wells Fargo &amp; Company raised their target price on shares of Amgen from $300.00 to $325.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Wednesday, December 10th. Finally, Piper Sandler lifted their target price on shares of Amgen from $342.00 to $381.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Amgen presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $332.85.</p>
<div class="lb-trans"><p>几家研究公司对安进发表了看法。Truist Financial 于 11 月 24 日星期一开始对安进进行覆盖。他们对该公司给予了 “持有” 评级，并设定了 318.00 美元的目标价。美国银行在 9 月 26 日星期五的研究报告中将安进的目标价从 261.00 美元上调至 272.00 美元，并给予该股票 “表现不佳” 的评级。高盛集团在 11 月 25 日星期二的研究报告中重申了对安进股票的 “买入” 评级。富国银行在 12 月 10 日星期三的研究报告中将安进股票的目标价从 300.00 美元上调至 325.00 美元，并给予该股票 “等权重” 的评级。最后，Piper Sandler 在 11 月 14 日星期五的研究报告中将安进股票的目标价从 342.00 美元上调至 381.00 美元，并给予该公司 “超配” 的评级。一位分析师对该股票给予了强烈买入评级，十位分析师给予了买入评级，十位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat，安进目前的平均评级为 “适度买入”，共识目标价为 332.85 美元。</p>
</div><p><strong>Check Out Our Latest Report on Amgen</strong></p>
<div class="lb-trans"><p><strong>查看我们关于安进的最新报告</strong></p>
</div><h2>Amgen Stock Performance</h2>
<div class="lb-trans"><h2>安进股票表现</h2>
</div><ul>
<li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>安进股票：在盈利超预期后，新的历史高点即将到来</li>
</ul>
</div><p>Shares of Amgen stock opened at $332.50 on Friday. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. The firm has a market capitalization of $179.04 billion, a P/E ratio of 25.70, a P/E/G ratio of 3.10 and a beta of 0.45. The business has a fifty day simple moving average of $322.29 and a two-hundred day simple moving average of $301.33. Amgen Inc. has a 12 month low of $257.05 and a 12 month high of $346.38.</p>
<div class="lb-trans"><p>安进股票在星期五开盘价为 332.50 美元。该公司的流动比率为 1.28，速动比率为 0.99，债务与股本比率为 5.45。该公司的市值为 1,790.4 亿美元，市盈率为 25.70，市盈增长比率为 3.10，贝塔系数为 0.45。该公司的 50 日简单移动平均为 322.29 美元，200 日简单移动平均为 301.33 美元。安进的 12 个月低点为 257.05 美元，12 个月高点为 346.38 美元。</p>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping analysts' consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company's revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>安进（NASDAQ:AMGN - 获取免费报告）最近于 11 月 4 日星期二发布了其财报。这家医疗研究公司报告了每股收益 5.64 美元，超出分析师一致预期的 5.01 美元，超出幅度为 0.63 美元。该公司在本季度的收入为 95.6 亿美元，而一致预期为 89.8 亿美元。安进的净利润率为 19.47%，股本回报率为 162.59%。与去年同期相比，该公司的收入增长了 12.4%。在去年同期，该公司每股收益为 5.58 美元。安进已将其 2025 财年指引设定为每股收益 20.600-21.400 美元。分析师平均预测安进在当前财年将发布每股收益 20.62 美元。</p>
</div><h2>Amgen Increases Dividend</h2>
<div class="lb-trans"><h2>安进增加股息</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be paid a dividend of $2.52 per share. This is a positive change from Amgen's previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, February 13th. Amgen's payout ratio is 73.57%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 3 月 6 日（星期五）支付。2 月 13 日（星期五）登记在册的股东将获得每股 2.52 美元的股息。这是对安进之前每股 2.38 美元季度股息的积极调整。这相当于年化 10.08 美元的股息，股息收益率为 3.0%。该股息的除息日期为 2 月 13 日（星期五）。安进的派息比率为 73.57%。</p>
</div><h2>Amgen Profile</h2>
<div class="lb-trans"><h2>安进简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.</p>
<div class="lb-trans"><p>安进公司（NASDAQ: AMGN）是一家成立于 1980 年，总部位于加利福尼亚州千橡市的全球生物技术公司。该公司专注于发现、开发、生产和提供针对严重疾病的人类治疗药物。安进的工作重点是基于细胞和分子生物学的生物药物，强调将人类遗传学和蛋白质科学的进展转化为患者的治疗方案。</p>
</div><p>Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.</p>
<div class="lb-trans"><p>安进的商业产品组合历来包括用于肿瘤学、支持性护理、肾脏病、骨骼健康和心血管疾病的生物制剂。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Washington prepares for war</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>The McDonald's Secret</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过安进</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>华盛顿为战争做准备</li>
<li>在 1 月 1 日之前投资 1000 美元于这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AMGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 AMGN 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取安进公司（NASDAQ:AMGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元于安进吗？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑安进之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而安进并不在其中。</p>
</div><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然安进目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pacer Advisors Inc. 减少了其在安进公司 $AMGN 的持股